Ranibizumab: all 350 studies that test it
Page 4 of 4. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME StudyWithdrawnNCT00676559Phase 1
- Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain BirthmarksWithdrawnNCT00667472Phase 1
- Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1CompletedNCT00657202Early Phase 1
- The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)Status unknownNCT00640640Not applicable
- Ranibizumab for Neovascularization in Sickle Cell RetinopathyWithdrawnNCT00618644Not applicable
- Lucentis for Age-related Macular Degeneration Pigment Epithelial DetachmentsCompletedNCT00590694Phase 2/3
- Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMDCompletedNCT00574093Phase 2
- Treatment of Failing Blebs With RanibizumabCompletedNCT00570726Phase 1
- Photodynamic and Pharmacologic Treatment of CNVCompletedNCT00570193Phase 1/2
- A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVOCompletedNCT00567697Phase 3
- Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)CompletedNCT00562406Not applicable
- Ranibizumab Versus PDT for Presumed Ocular HistoplasmosisStatus unknownNCT00546936Phase 2
- Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque RadiotherapyStatus unknownNCT00540930Phase 4
- Evaluation of Dosing Interval of Higher Doses of RanibizumabCompletedNCT00533520Phase 4
- Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring VitrectomyStatus unknownNCT00516464Phase 3
- Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)CompletedNCT00510965Phase 2
- Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT00504959Phase 4
- Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)CompletedNCT00504400Phase 2
- CAPTAIN:Choroidal Neovascularization Assessment by Pattern ElectroretinographyCompletedNCT00500344Phase 1
- Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related MaculopathyCompletedNCT00470977Phase 1/2
- EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)CompletedNCT00470678Phase 3
- A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMDCompletedNCT00469352Phase 3
- Scotoma Reduction in AMD Patients Treated With RanibizumabCompletedNCT00467935Phase 1/2
- Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by ItselfWithdrawnNCT00457678Phase 2
- Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel FormationCompletedNCT00457145Phase 1
- Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel FormationCompletedNCT00457067Phase 1
- Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMDStatus unknownNCT00455871Not applicable
- Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular EdemaCompletedNCT00440609Phase 1/2
- Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNVCompletedNCT00429962Phase 3
- Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)CompletedNCT00413829Phase 2
- Lucentis for Central Retinal Vein Occlusion (CRVO)CompletedNCT00406796Phase 1
- Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein OcclusionCompletedNCT00406471Phase 1
- Intravitreal Ranibizumab Treatment of Central Serous ChorioretinopathyCompletedNCT00403325Phase 1
- Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular DegenerationWithdrawnNCT00403156Phase 1
- Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular EdemaCompletedNCT00403039Phase 1
- Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular DegenerationCompletedNCT00395707Phase 1/2
- Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.CompletedNCT00395551Phase 1
- Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular DegenerationCompletedNCT00390208Phase 2
- Efficacy Study of Lucentis in the Treatment of Diabetic Macular EdemaCompletedNCT00387582Phase 2
- Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) TrialCompletedNCT00378196Phase 1
- An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMDCompletedNCT00373659Phase 2
- Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)CompletedNCT00344227Phase 2
- Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular DegenerationCompletedNCT00288561Phase 2
- A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00251459Phase 3
- Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)CompletedNCT00095433Phase 3
- A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00090623Phase 3
- Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau SyndromeCompletedNCT00089765Phase 1
- A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular DegenerationCompletedNCT00061594Phase 3
- A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular DegenerationCompletedNCT00056836Phase 3
- Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)CompletedNCT00056823Phase 1/2